Novel Compound May Shut Down Pancreatic and Triple Negative Breast Cancer Cells

Dr. Patrick Griffin PhD Professor and Chairman Department of Molecular Therapeutics Director of the Translational Research Institute Scripps Research Institute, Jupiter, FloridaMedicalResearch.com Interview with:
Dr. Patrick Griffin PhD

Professor and Chairman Department of Molecular Therapeutics
Director of the Translational Research Institute
S
cripps Research Institute, Jupiter, Florida

MedicalResearch.com: What is the background for this study? What are the main findings?

Dr. Griffin: We identified a novel synthetic compound known as SR1848 that sharply inhibits the activity and expression of “liver receptor homolog-1” or LRH-1, a protein that plays an important role in the progression of breast and pancreatic cancers.

Our new study shows that SR1848 removes LRH1 from DNA, shutting down expression of LRH-1 target genes, and halts cell proliferation. It’s a novel compound that appears to be a promising chemical scaffold for fighting tumors that are non-responsive to standard therapies.

MedicalResearch.com: What should clinicians and patients take away from your report?

Dr. Griffin: LRH-1 has been implicated in the proliferation and metastasis of estrogen receptor-positive breast cancers and the more difficult to treat estrogen receptor-negative breast cancers. Our new findings suggest that repressing LRH-1 could be useful in treating the more aggressive triple-negative breast cancer subtype where therapies are currently so limited.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Dr. Griffin: Our new compound also appears attractive as a potential therapeutic because of its lack of impact on cells that do not express LRH1, which could mean few potential side effects.

Citation:

Antiproliferation activity of a small molecule repressor of liver receptor homolog 1.

Mol Pharmacol. 2015 Feb;87(2):296-304. doi: 10.1124/mol.114.095554. Epub 2014 Dec 3.

No Comments

Sorry, the comment form is closed at this time.